The company behind weight-loss jab Wegovy and diabetes drug Ozempic will have a boardroom clear-out, with seven board members including the chairman set to depart.
Novo Nordisk on Tuesday said chairman Helge Lund, vice chair Henrik Poulsen and five directors will not stand for re-election at an extraordinary investor meeting in November.
It's the latest in a raft of changes at the Danish company, which welcomed a new chief executive in August and announced it would lay off 9,000 staff in September.
Last month the firm issued a warning on profits due to increased competition from US rivals, and announced a cost-savings programme as it cut its profit growth forecast for the third time this year.
Widespread adoption of Novo Nordisk's Ozempic diabetes treatment, which is often used off-label as a weight loss drug, and Wegovy had boosted its share price to the point where in summer 2024 it was Europe's most-valuable company.
